DMTN Knockout K-562 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of human chronic myeloid leukemia cells harboring a disrupted DMTN gene. This heterogeneous pool of edited cells carries distinct genetic modifications that collectively result in functional loss of the dematin protein. The polyclonal format avoids clonal selection bottlenecks and captures a spectrum of editing outcomes, providing a robust model for studying DMTN-dependent processes in a leukemia background.
The K-562 cell line was established from a 53-year-old female with CML in blast crisis and carries the Philadelphia chromosome, leading to constitutive BCR-ABL1 kinase activity. These cells serve as a canonical model for BCR-ABL-driven leukemogenesis, apoptosis, and hematopoietic differentiation and are routinely used in preclinical evaluation of tyrosine kinase inhibitors like imatinib.
DMTN encodes dematin, an actin-binding and bundling protein that is a key component of the erythrocyte membrane skeleton and also functions in non-erythroid cells. Its activity is regulated by calmodulin binding and phosphorylation by protein kinase C and cAMP-dependent protein kinase. Dematin interacts with F-actin and partners such as ??-actinin, spectrin, adducin, and tropomyosin, and acts downstream of RHO GTPase effectors. Loss of DMTN disrupts actin filament organization and membrane skeleton integrity, impairing cell adhesion, spreading, and migration, and altering actomyosin contractility and actin-dependent signaling.
In K-562 cells, DMTN knockout creates a disease-relevant model to study how cytoskeletal disorganization influences leukemic cell behavior. This disruption compromises membrane stability and migration, processes linked to leukemia homing and drug resistance. The BCR-ABL-driven background enables investigation of crosstalk between oncogenic kinases and actin regulatory pathways. Moreover, since DMTN mutations cause hereditary spherocytosis and elliptocytosis, these cells provide a malleable system for mechanistic dissection of membrane skeletonopathies.
Researchers can use these polyclonal knockout cells in quantitative immunofluorescence of F-actin, western blotting for phospho-signaling intermediates, flow cytometry for cell cycle and apoptosis, and transwell migration assays. The model is especially suited for imatinib dose-response studies to evaluate how actin pathway alterations modulate drug sensitivity. Because the population is polyclonal, it captures heterogeneous editing effects without clonal bias. For further information, please contact Ascent Research.
